Residual lung abnormality following COVID-19 hospitalisation is characterised by biomarkers of epithelial injury.
Stewart I, Jacob J, Porter JC, Liu B, Tatler AL, Gomez N, Pugh MR, John AE, Allen RJ, Blaikley JF, Chaudhuri N, Denneny E, Fabbri L, George PM, Guillen-Guio B, Gooptu B, Hall IP, Ho LP, Jarrold I, Johnson S, Jones MG, Khan F, Mehta P, Mitchell J, Molyneaux PL, Pearl JE, Piper Hanley K, Platé M, Quinn V, Rivera-Ortega P, Saunders LC, Smith DJF, Spears M, Spencer LG, Stanel SC, Thompson AAR, Walsh S, Wild JM, Wootton DG, Docherty AB, Gleeson F, Greenhalf W, Harrison EM, Lone N, Quint J, Maslova A, Pohl M, Stephens A, Young S, Singapuri A, Shikotra A, Sereno M, Saunders RM, Richardson M, Raman B, Poinasamy K, McAuley HJC, Marks M, Leavy OC, Houchen-Wolloff L, Horsley A, Harris VC, Greening N, Evans RA, Elneima O, Chalmers JD, Brightling CE, Chambers RC, Wain LV, Jenkins RG; PHOSP-COVID Collaborative Group and the UKILD Consortium.
Stewart I, et al.
EBioMedicine. 2026 Feb;124:106134. doi: 10.1016/j.ebiom.2026.106134. Epub 2026 Jan 24.
EBioMedicine. 2026.
PMID: 41581494
Free PMC article.